RecruitingPhase 4NCT05408247
A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder
Sponsor
University of Sydney
Enrollment
280 participants
Start Date
Feb 16, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called N-acetyl cysteine and a drug called Placebo for people with alcohol use disorder (aud). The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 70 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGN-acetyl cysteine
2400mg/day
DRUGPlacebo
Matched placebo
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05408247
Related Trials
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT075595001 location
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
NCT064840751 location
Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974
NCT074888191 location
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
NCT061361952 locations
Optimizing Smart Technology for Addiction Recovery
NCT075735401 location